Bio-interventional cyclodialysis and cataract surgery approach comparable to other MIGS procedures
A study presented at the AGS 2026 Annual Meeting showed an 8.7% reduction in endothelial cell count (ECC) through 24 months in eyes undergoing combined phacoemulsification cataract surgery and bio-interventional ab-interno cyclodialysis with scleral allograft reinforcement.
The researchers used interim data from the real-world, multicenter, prospective CREST study and included 41 evaluable eyes undergoing anterior chamber-clear homologous allogeneic bio-tissue reinforcement for ab-interno cyclodialysis combined with cataract surgery.
The mean baseline ECC was 2413 cells/mm². At 12 and 24 months, mean ECC was 2283 cells/mm² and 2200 cells/mm², respectively, indicating a paired reduction of 8.7% over the 2-year period. There were no differences in mean ECC between 12 and 24 months.
“Concomitant cataract surgery plus bio-interventional cyclodialysis had a minimal effect on ECC, comparable to other FDA-approved minimally invasive glaucoma procedures and cataract surgery alone,” the authors concluded.
Longer-term data in a larger patient cohort will be important to validate the results.
Reference
Sheybani A, Chaya CJ, Radcliffe NM, Chang RT, Weinreb R. Endothelial health after bio-interventional scleral allograft reinforcement and ab interno cyclodialysis in eyes undergoing cataract surgery: 24M results. Poster presented at: American Glaucoma Society Annual Meeting; February 19-22, 2026; Rancho Mirage, CA.
Related Content
